FDA Approves Drug-Device Combo to Detect Residual Cancer After Lumpectomy

The FDA has approved Lumisight (pegulicianine), an optical imaging agent, to illuminate residual breast cancer.

Related Keywords

Howard Hechler ,Drug Administration ,Lumicell Direct Visualization System ,Chief Operating Officer ,